Journal of Medical Virology最新文献

{"title":"Correction to “Serum-Derived Bovine Immunoglobulin Treatment in COVID-19 Is Associated With Faster Resolution of Symptoms: A Randomized Pilot Clinical Trial”","authors":"","doi":"10.1002/jmv.70202","DOIUrl":"10.1002/jmv.70202","url":null,"abstract":"<p>N. S. Utay, R. Güerri-Fernández, S. Gharakhanian, et al., “Serum-Derived Bovine Immunoglobulin Treatment in COVID-19 Is Associated With Faster Resolution of Symptoms: A Randomized Pilot Clinical Trial,” <i>Journal of Medical Virology</i> 96, no. 10 (2024): e70005.</p><p>A significant member of our clinical operations team was inadvertently left out of the “Acknowledgments” section of the article. Dr. Ana Maria Aldea Perona, Head of Clinical Research Unit at Hospital del Mar in Barcelona, and the Clinical Research Unit team assisted with the clinical operations, as well as the design of the protocol, statistics, the patient information sheet, variable definitions, and the case report form. Because of Dr. Aldea Perona and her team's contribution, the sentence in the “Acknowledgements” section starting with “We would also like to thank…” should be updated to “We would also like to thank Dr. Ana Maria Aldea Perona and the Clinical Research Unit at Hospital del Mar for assistance with the study design and clinical operations, Dr. Silvia Castañeda, Dr. Silvia Gómez-Zorrilla, and Dr. Elena Sendra for conducting the fieldwork for the study, and Duke Duguay as medical writer and EarlyPhase Sciences for data analyses.”</p><p>We apologize for this error.</p>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 2","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70202","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dengue Virus Replicative-Form dsRNA Is Recognized by Both RIG-I and MDA5 to Activate Innate Immunity","authors":"Sichao Ye,&nbsp;Yisha Liang,&nbsp;Yu Chang,&nbsp;Bailiang Lai,&nbsp;Jin Zhong","doi":"10.1002/jmv.70194","DOIUrl":"10.1002/jmv.70194","url":null,"abstract":"<div>\u0000 \u0000 <p>RIG-I like receptors (RLRs) are a family of cytosolic RNA sensors that sense RNA virus infection to activate innate immune response. It is generally believed that different RNA viruses are recognized by either RIG-I or MDA5, two important RLR members, depending on the nature of pathogen-associated molecular patterns (PAMPs) that are generated by RNA virus replication. Dengue virus (DENV) is an important RNA virus causing serious human diseases. Despite extensive investigations, the molecular basis of the DENV PAMP recognized by the host RLR has been poorly defined. Here, we demonstrated that the DENV infection-induced interferon response is dependent upon both RIG-I and MDA5, with RIG-I playing a predominant role. Next we purified the DENV PAMP RNA from the DENV-infected cells, and demonstrated that the purified DENV PAMP is viral full-length double-stranded RNA bearing 5'ppp modifications, likely representing the viral replicative-form RNA. Finally, we confirmed the nature of the DENV PAMP by reconstituting the viral replicative-form RNA from in vitro synthesized DENV genomic RNA. In conclusion, our work not only defined the molecular basis of the RLR-PAMP interaction during DENV infection, but also revealed the previously underappreciated recognition of a distinct moiety of the same PAMP by different RLRs in innate immunity against RNA viruses.</p>\u0000 </div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 2","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vacuolated Parabasal Cells in Papanicolaou Smears Are Cellular Changes Caused by Human Papillomavirus 16 Infection","authors":"Shuichi Mizuno,&nbsp;Kaori Okayama,&nbsp;Yukimi Misawa,&nbsp;Saeka Honda,&nbsp;Rei Settsu,&nbsp;Ruku Shinohara,&nbsp;Yasuyoshi Ishii,&nbsp;Masahiko Fujii,&nbsp;Mizue Oda,&nbsp;Mitsuaki Okodo","doi":"10.1002/jmv.70191","DOIUrl":"10.1002/jmv.70191","url":null,"abstract":"<div>\u0000 \u0000 <p>In cervical cancer screening, cytology is used as a triage test to refer high-risk human papillomavirus (HR-HPV)-positive women for colposcopy, but its accuracy is inadequate. The present study aimed to demonstrate that the presence of atypical cells with large vacuoles in the cytoplasm of parabasal cells, referred to as vacuolated parabasal cells (VPCs), which are observed in the Pap smears of HPV-positive women, is associated with specific HPV genotypes. Among 2175 patients, 310 with a single HR-HPV infection and cytological diagnosis of high-grade squamous intraepithelial lesions (HSIL) or atypical squamous cells not excluding HSIL (ASC-H) were included, of which 86 were infected with HPV16. Biopsy results revealed that 69 (80.2%) patients had cervical intraepithelial neoplasia Grade 2 or higher (CIN2+). VPCs were found in 47 (54.7%) of HPV16-infected cases, indicating a significant increase of VPCs in HPV16-infected cases (<i>p</i> &lt; 0.01). Episomal HPV16 load was quantified in 142 VPCs and 156 HSIL (ASC-H) cells using liquid-based cytology samples from five patients, with a median of 987 copies in VPCs, significantly higher than those in HSIL (ASC-H) cells (176 copies; <i>p</i> &lt; 0.001). VPCs in Pap specimens were identified not only as cells altered by HPV16 infection but also as CIN2+-derived cells and HPV16-producing cells.</p>\u0000 </div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 2","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Viral Coinfections in Blood Donors in Bahia, Brazil","authors":"Estela Luz,&nbsp;Marinho Marques,&nbsp;María B. Arriaga,&nbsp;Luísa Meireles Campos,&nbsp;Lara Lima,&nbsp;Sávio Amaral,&nbsp;Eduardo Luz Marques,&nbsp;Kimberly Page,&nbsp;Carlos Brites","doi":"10.1002/jmv.70186","DOIUrl":"10.1002/jmv.70186","url":null,"abstract":"<div>\u0000 \u0000 <p>Human Immunodeficiency Virus (HIV), Human T Lymphotropic Virus (HTLV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) coinfection may lead to disease progression or worsen its clinical presentation. Viral coinfections screening during blood donation is critical. To identify risk factors for coinfection among blood donors, we assessed the blood donations at the Fundação de Hematologia e Hemoterapia da Bahia, from 2008 to 2017. We compared serological/molecular evidence of single infection versus two or more viral blood-borne infections—BBI). A multivariable logistic regression model was performed to evaluate independent associations between characteristics of donors with single infection and multiple infection using “non-infection” category as reference. Among 777,446 collected blood donations, 27 358 (3.5%) were reactive, most (<i>n</i> = 26 677, 97.6%) for a single infection and 681 (2.4%) for coinfection. The most frequent coinfections were HBV-HIV (30.6%), HBV-HCV (30.4%), and HBV-HTLV (24.4%). Male sex, lower education, being single, and being a first-time donor were independently associated with both single and coinfections. Nevertheless, the adjusted odds for risk factors of coinfections were much higher than those for single infection. Donors with single and coinfection for BBI shared identical risks, but they were significantly higher for coinfection. Preventive strategies addressing the identified risks can decrease transmission of viral BBI by blood transfusion.</p></div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 2","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Building a Bridge Between the Mechanism of EBV Reactivation and the Treatment of EBV-Associated Cancers","authors":"Jialin Jiang,&nbsp;Xinlei Zhu,&nbsp;Shukun Li,&nbsp;Qun Yan,&nbsp;Jian Ma","doi":"10.1002/jmv.70192","DOIUrl":"10.1002/jmv.70192","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 <p>Epstein-Barr virus (EBV) infection is closely associated with the development of various tumors such as lymphomas and epithelial cancers. EBV has a discrete life cycle with latency and lytic phases. In recent years, significant progress has been made in the understanding of the mechanism underlying the transition of EBV from latency to lytic replication. Multiple new lytic activation factors have been emerged and promoted our understanding of this field. In addition, we have comprehensively presented the existing therapeutic strategies and their relationship to the mechanism underlying the transition of EBV from latency to lytic replication in this review, such as lytic induction therapy and drugs to prevent EBV from entering the lytic phase fully utilize the EBV reactivation mechanisms. This year marks the 60th anniversary of the discovery of EBV, and building a bridge between the mechanism of EBV reactivation and the treatment may help us to design new approaches for treating EBV-associated diseases.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 2","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel HTNV Budding Inhibitor Interferes the Interaction Between Viral Glycoprotein and Host ESCRT Accessory Protein ALIX","authors":"Qikang Ying,&nbsp;Xiaoxiao Zhang,&nbsp;Shengzheng Wang,&nbsp;Tianle Gu,&nbsp;Junmei Zhang,&nbsp;Wenjie Feng,&nbsp;Dongjing Li,&nbsp;Yuhang Dong,&nbsp;Xingan Wu,&nbsp;Fang Wang","doi":"10.1002/jmv.70182","DOIUrl":"10.1002/jmv.70182","url":null,"abstract":"<div>\u0000 \u0000 <p>Virus budding is a critical step in the replication cycle of enveloped viruses, closely linked to viral spread, disease progression, and clinical outcomes. The budding of many enveloped RNA viruses is facilitated by the hijacking of the host endosomal sorting complex required for transport (ESCRT) proteins through viral late domains. These late domains are essential for progeny virus production and are highly conserved, making the interaction between late domains and host ESCRT proteins a potential target for the development of antiviral therapeutics. In this study, we elucidated the functional role of the conserved YRTL motif within the glycoprotein Gn cytoplasmic tail of <i>Orthohantavirus hantanense</i> (Hantaan virus, HTNV), demonstrating that HTNV production is regulated by the interaction between YRTL and the ESCRT accessory protein ALIX (ALG-2 interacting protein X). Through virtual molecule docking screening, followed by in vitro and in vivo assays, we discovered a novel compound, AN-329, which disrupts the YRTL−ALIX interaction and effectively inhibits infectious HTNV production, as well as Crimean−Congo hemorrhagic fever virus (CCHFV) and Rift Valley fever virus (RVFV) VLP release. This makes AN-329 a promising therapeutic candidate for reducing viral dissemination. Given that YRTL is conserved across many hantaviruses, our findings may serve as a prototype for the development of broad-spectrum antiviral drugs.</p></div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 2","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low Neutralization of SARS-CoV-2 Omicron BA5248, XBB15 and JN1 by Homologous Booster and Breakthrough Infection","authors":"Jianhua Li,&nbsp;Hao Yan,&nbsp;Jiaxuan Li,&nbsp;Feng Ling,&nbsp;Yan Feng,&nbsp;Haiyan Mao,&nbsp;Xingxing Wang,&nbsp;Xiaoyan Li,&nbsp;Wanchen Song,&nbsp;Guangshang Wu,&nbsp;Yanjun Zhang,&nbsp;Yin Chen,&nbsp;Keda Chen","doi":"10.1002/jmv.70189","DOIUrl":"10.1002/jmv.70189","url":null,"abstract":"<p>Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can be induced through either infection with the virus or vaccination, providing protection against reinfection or reducing the risk of severe clinical outcomes. In this study, we recruited 172 volunteers who received different vaccination regimens, including 124 individuals who had recovered from breakthrough infections caused by the Omicron variant (27 with 2 doses, 49 with 3 doses, and 48 with 4 doses) and 48 healthy donors who did not experience breakthrough infections (all of whom received a fourth dose during the infection wave). We measured neutralizing antibody levels against Omicron BA.5.2.48, XBB.1.5, and JN.1 and found no significant differences in neutralizing antibody titers between natural infection and homologous booster vaccination at 6 months (<i>p</i> &gt; 0.05), with geometric mean titers declining by over 100-fold for some variants relative to the prototype strain.</p>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 2","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11771737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of HBV Therapy on Glycemic Control in HBV-Infected Patients With Diabetes: A 90-day Multicenter Study","authors":"Qi Liu,&nbsp;Jie Huang,&nbsp;Jingyi Hu,&nbsp;Yujing Ding,&nbsp;Yue Wang,&nbsp;Pan Zhang,&nbsp;Zhenlan Zhang,&nbsp;Ying Liu,&nbsp;Boqi Li,&nbsp;Biao Xiao,&nbsp;Ting Cai,&nbsp;Tingting Yue,&nbsp;Xia Li,&nbsp;Mahmoud Reza Pourkarim,&nbsp;Erik De Clercq,&nbsp;Zhiguang Zhou,&nbsp;Yang Xiao,&nbsp;Guangdi Li","doi":"10.1002/jmv.70185","DOIUrl":"10.1002/jmv.70185","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 <p>Patients with diabetes are at increased risk of HBV infection; however, the effects of HBV infection and anti-HBV therapy on the management of type 1 diabetes (T1D), type 2 diabetes (T2D), and latent autoimmune diabetes in adults (LADA) remain unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 <p>From 2016 to 2023, we recruited a multicenter cohort of 355 HBV-infected inpatients, including 136 with T1D, 140 with T2D, and 79 with LADA. The control group included 525 HBV-uninfected inpatients, comparing 171 with T1D, 204 with T2D and 150 with LADA. We employed propensity-score matching between cases and controls to minimize confounding effects. Hemoglobin A1c (HbA1c) was monitored at baseline and at months 1, 2, and 3.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 <p>At baseline, median HbA1c was significantly higher in HBV-infected patients compared to their HBV-uninfected controls: T1D (10.4% vs<i>.</i> 7.5%, <i>p</i> &lt; 0.01), T2D (9.6% <i>vs.</i> 8.6%, <i>p</i> = 0.01), and LADA (9.4% vs<i>.</i> 8.4%, <i>p</i> = 0.03). Baseline HbA1c levels were significantly lower in HBV-treated patients compared to those HBV-untreated patients, regardless of whether they were on antidiabetic therapy (<i>p</i> &lt; 0.05). A 90-day follow-up consistently indicated lower HbA1c levels at baseline, as well as at months 1, 2, and 3 among HBV-treated patients with T1D, T2D, or LADA. Both univariate and multivariate analyses identified HBV therapy (OR = 0.44, <i>p</i> &lt; 0.001) and antidiabetic treatment(OR = 0.51, <i>p</i> = 0.031) as protective factors for glycemic control in HBV-infected patients with diabetes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 <p>Poor glycemic control is found in HBV-infected patients with diabetes, but the intervention of anti-HBV therapy and antidiabetic treatment contributes to improved glycemic control in HBV-infected patients with T1D, T2D, or LADA.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 2","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fullerene (C60 & C70)-Meso-Tris-4-Carboxyphenyl Porphyrin Dyads Inhibit Entry of Wild-Type and Drug-Resistant HIV-1 Clades B and C","authors":"Debdulal Sharma,&nbsp;Madhu Rai,&nbsp;Aradhana Singh,&nbsp;Ritu Gaur,&nbsp;Devashish Senguptaa","doi":"10.1002/jmv.70181","DOIUrl":"10.1002/jmv.70181","url":null,"abstract":"<div>\u0000 \u0000 <p>The biological applications of noncationic porphyrin-fullerene (P-F) dyads as anti-HIV agents have been limited despite the established use of several cationic P-F dyads as anti-cancer photodynamic therapy (PDT) agents. This article explores the potential of amphiphilic non-cationic porphyrin-fullerene dyads as HIV-1 inhibitors under both PDT (light-treated) and non-PDT (dark) conditions. The amphiphilic P-F dyads, <b>PB</b>_<b>3</b><b>C</b>_<b>60</b> and <b>PB</b>_<b>3</b><b>C</b>_<b>70</b>, demonstrated enhanced efficacy in inhibiting the entry and production of HIV-1 (subtypes B and C). Under light-harvested conditions, the dyads exhibited potent inhibitory effects (EC₅₀ for <b>PB</b>_<b>3</b><b>C</b>_<b>60</b> and <b>PB</b>_<b>3</b><b>C</b>_<b>70</b> &lt; 10 nM) and also maintained significant inhibition under non-PDT conditions (EC₅₀ for <b>PB</b>_<b>3</b><b>C</b>_<b>60</b> = 1.43 μM and <b>PB</b>_<b>3</b><b>C</b>_<b>70</b> = 1.50 μM), while displaying notably reduced toxicity compared to their water-soluble porphyrin precursor. The P-F dyads exhibited substantial efficacy in neutralizing the T20-resistant strain 9491, both at the entry and postentry phases, thereby addressing the challenge of drug resistance.</p></div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 2","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B","authors":"Log Young Kim,&nbsp;Jae Young Kim,&nbsp;Jeong-Ju Yoo,&nbsp;Sang Gyune Kim,&nbsp;Young-Seok Kim","doi":"10.1002/jmv.70187","DOIUrl":"10.1002/jmv.70187","url":null,"abstract":"<div>\u0000 \u0000 <p>While entecavir (ETV) and tenofovir disoproxil fumarate (TDF) effectively manage chronic hepatitis B, their long-term effects on lipid metabolism and cardiovascular outcomes remain unclear. This study compares the impact of ETV, TDF, and treatment-naïve (control group) on hyperlipidemia and major adverse cardiac events (MACE) in people living with chronic hepatitis B (PLWHB). We used claim data from the South Korean National Health Insurance Service. Propensity score matching was used to account for confounding factors. The 5-year cumulative incidence of dyslipidemia was 7.10% for TDF, 12.17% for ETV, and 18.55% for the control group, with incidence rates per 1000 person-years of 14.5, 25.5, and 38.9, respectively. TDF showed a significantly lower risk of dyslipidemia compared to ETV (IRR: 0.56, <i>p</i> &lt; 0.001) and the control group, which was confirmed in Cox regression analysis (HR: 0.392 vs. control, <i>p</i> &lt; 0.001). For MACE, the 5-year cumulative incidence was 9.11% for TDF, 10.98% for ETV, and 12.32% for the control group, with incidence rates per 1000 person-years of 18.4, 22.5, and 24.8, respectively. TDF demonstrated a reduced risk compared to ETV (IRR: 0.817, <i>p</i> &lt; 0.001), which was similarly supported by Cox regression analysis (HR: 0.728 vs. control, <i>p</i> &lt; 0.001). In conclusion, TDF not only reduces the risk of hyperlipidemia but is also associated with a reduced risk of MACE compared to ETV or treatment-naive group in PLWHB.</p>\u0000 </div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 2","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}